Compare BEEM & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | TVRD |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 27.5M |
| IPO Year | 2018 | 2013 |
| Metric | BEEM | TVRD |
|---|---|---|
| Price | $1.13 | $1.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $3.50 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 294.4K | 189.8K |
| Earning Date | 04-09-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 40.77 | ★ 79.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,236,000.00 | $911,000.00 |
| Revenue This Year | $40.48 | N/A |
| Revenue Next Year | $32.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 959.30 |
| 52 Week Low | $0.97 | $0.93 |
| 52 Week High | $4.04 | $43.65 |
| Indicator | BEEM | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 34.20 | 34.74 |
| Support Level | $1.09 | N/A |
| Resistance Level | $1.66 | $2.02 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 1.52 | 35.51 |
Beam Global is a clean-technology innovation company. It develop, design, engineer, manufacture, and sell high-quality, renewably energized infrastructure products for electric vehicle ( EV ) charging, infrastructure for Smart Cities (the interconnected physical and digital elements within a city that utilize technology to enhance efficiency, sustainability, and quality of life for residents), energy security and disaster preparedness and energy-dense battery solutions in safe, compact and form-factors. Additionally, the company manufactures structures with electronic integration such as streetlighting, cell towers and energy infrastructure products as well as power electronics including invertors, charge controllers, power supplies and LED lighting.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.